February 22, 2012 at 08:52:02 EST by Proactive Investors
IntelliCell BioScience (OTCQB:SVFC.PK) said Tuesday that its stromal vascular fraction (SVF) stem cell therapy was featured in an article in the New York Daily News over the weekend.
The company, through its proprietary technology, processes stromal vascular fraction (SVF) stem cells, derived from one's own body fat.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for anti-aging effects, as well as for the treatment of more serious conditions like arthritis, congestive heart failure, gum recession, and wound healing.
IntelliCell's SVF cells can be used to treat certain conditions, or rejuvinate damaged tissue and cell function. The company, which under the FDA is authorized to commercially sell its SVF cells, has also applied for a patent on its use of ultrasonic cavitations to break up fat cells, which increases the number of SVF stem cells that can be extracted from just two ounces of fat to between 500 million and 1.4 billion.
A full page Daily News article, titled “Stem Sells” written by Sean Brennan published February 19, 2012, http://www.nydailynews.com/sports/college/manhattan-basketball-torgrim-sommerfeldt-turned-stem-cell-treatment-back-court-article-1.1025227, describes how Torgrim Sommerfeldt’s budding basketball career was saved through Dr. Anthony Maddalo’s treatment using IntelliCell's proprietary SVF cell therapy.
Sommerfeldt, a former star player for the Norwegian National Basketball Team, had undergone six knee surgeries, and had forfeited his Wake Forest basketball scholarship.
Proactive Investors
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in London, New York, Sydney and Toronto
© 2008-2011 Copyright 